Cedrik M. Britten
Chief Tech/Sci/R&D Officer bij IMMATICS N.V.
Vermogen: 2 M $ op 31-03-2024
Actieve functies van Cedrik M. Britten
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
IMMATICS N.V. | Chief Tech/Sci/R&D Officer | 01-06-2020 | - |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 01-06-2020 | - |
Loopbaan van Cedrik M. Britten
Eerdere bekende functies van Cedrik M. Britten
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
GSK PLC | Corporate Officer/Principal | 01-02-2015 | 01-05-2020 |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Chief Tech/Sci/R&D Officer | 01-06-2010 | 01-01-2015 |
Opleiding van Cedrik M. Britten
The Johannes Gutenberg University of Mainz | Doctorate Degree |
Statistieken
Internationaal
Duitsland | 5 |
Verenigd Koninkrijk | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
GSK PLC | Health Technology |
IMMATICS N.V. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Health Technology |
- Beurs
- Insiders
- Cedrik M. Britten
- Ervaring